Alcon Inc. (ALC)
| Market Cap | 37.14B |
| Revenue (ttm) | 10.03B |
| Net Income (ttm) | 1.07B |
| Shares Out | 494.40M |
| EPS (ttm) | 2.16 |
| PE Ratio | 34.61 |
| Forward PE | 22.61 |
| Dividend | $0.22 (0.29%) |
| Ex-Dividend Date | May 14, 2025 |
| Volume | 2,445,095 |
| Open | 75.08 |
| Previous Close | 75.40 |
| Day's Range | 74.80 - 75.41 |
| 52-Week Range | 71.55 - 99.20 |
| Beta | 0.69 |
| Analysts | Buy |
| Price Target | 93.32 (+24.24%) |
| Earnings Date | Nov 11, 2025 |
About ALC
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ... [Read more]
Financial Performance
In 2024, Alcon's revenue was $9.91 billion, an increase of 4.82% compared to the previous year's $9.46 billion. Earnings were $1.02 billion, an increase of 4.52%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ALC stock is "Buy." The 12-month stock price target is $93.32, which is an increase of 24.24% from the latest price.
News
Broadwood Partners Issues Letter to STAAR Surgical's Board Urging it to Allow Timely Shareholder Vote on Alcon Sale
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (...
Broadwood Partners: All Three Leading Proxy Advisory Firms Recommend STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Institutional Shareholder Services Inc. (“ISS”), a leading independent proxy advisory ...
Broadwood Partners Comments on STAAR Surgical's Late and Troubling Disclosure in Deeply Flawed Sale Process to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on the recent Current Report on Form 8-K filed by STAAR Surgical Company (“STAAR” or the “C...
Broadwood Partners Issues Letter to STAAR Surgical's Board Questioning Its Diligence in Rush to Reaffirm Support for Alcon Sale
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (...
STAAR Surgical Board of Directors Reiterates Unanimous Recommendation that STAAR Stockholders Vote “FOR” the Alcon Merger Agreement on WHITE Proxy Card
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correc...
Broadwood Partners: Leading Advisory Firm Glass Lewis Urges STAAR Shareholders to Vote “AGAINST” Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading independent proxy advisory firm, ha...
Broadwood Partners Questions Integrity of STAAR Surgical's Last-Minute Forecast Change and Fairness Opinion in Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today sent the following letter to the shareholders of STAAR Surgical Company (“STAAR” or the “Company”) (N...
Defender Capital Opposes STAAR Surgical's Proposed Sale to Alcon
CHARLOTTE, N.C. , Oct. 7, 2025 /PRNewswire/ -- Defender Capital ("Defender" or "we"), a long-term shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) owning approximately 1...
Yunqi Capital, One of STAAR Surgical Company's Largest Shareholders, Reiterates Its Opposition to the Proposed Merger with Alcon
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company...
Broadwood Partners Issues Letter to STAAR Surgical's Board Questioning Its Judgment in Proposed Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (...
STAAR Surgical: Independent Industry Analysts Recognize Merits of Alcon Merger, the Value It Provides, and the Downside Risks Facing STAAR on Standalone Basis
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Johnson Fistel Investigates Fairness of Proposed Sale of STAAR Surgical
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP continues its investigation into whether the board members of STAAR Surgical Company (NASDAQ: STAA) breach...
Broadwood Partners Publishes Presentation Detailing Opposition to STAAR Surgical's Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”), holders of approximately 27.5% of the outstanding common stock of STAAR Surgical Company (“STAAR” or...
Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon's Acquisition of STAAR
GENEVA & LAKE FOREST, Calif.--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), th...
Alcon: Seeing Is Believing As Buyout Of STAAR Surgical Hangs In Balance
Alcon Inc. gets upgraded to a Buy again after my prior hold rating. Upside could come from macro-level clinical demand in the eyecare niche, but also a diverse and growing product portfolio in both th...
STAAR Surgical Publishes Presentation Highlighting Compelling, Certain Cash Value Offered by Alcon Merger and Meaningful Downside Risks if Alcon Merger is not Approved
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
STAAR Surgical Announces Expiration of “Window Shop” Period; No Competing Acquisition Proposals Received
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Yunqi Capital, 5.1% Holder and One of STAAR Surgical Company's Largest Shareholders, Announces Intention to Vote Against the Proposed Sale to Alcon
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company...
STAAR Surgical Board of Directors Unanimously Believes Alcon Merger Maximizes Value for STAAR Stockholders
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with UNITY VCS
GENEVA--(BUSINESS WIRE)--Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with UNITY VCS.
Eye care giant Alcon acquires LumiThera, a Seattle-area startup behind device that treats vision loss
LumiThera's key innovation is a device for use by ophthalmologists that improves vision and slows its loss, with a focus on patients with dry age-related macular degeneration.
Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025
GENEVA--(BUSINESS WIRE)--Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025.
Alcon to Present at 2025 Baird Global Healthcare Conference
GENEVA--(BUSINESS WIRE)--Alcon to Present at 2025 Baird Global Healthcare Conference.
Trouble Ahead for Alcon Shares
Alcon Inc. is showing clear signs of weakness on its weekly chart. The stock has entered Phase 8 of its 18-phase Adhishthana cycle, and a critical breakdown from its Cakra formation has triggered what...
These Analysts Slash Their Forecasts On Alcon After Q2 Earnings
Alcon Inc ALC posted better-than-expected earnings for the second quarter and cut its 2025 outlook late on Tuesday, citing increased tariff impact.